Type 2 diabetes mellitus. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Receiving F. assa-foetida capsule called Asafin at dose of 250 mg twice daily for 3 mounts. It is necessary to mention that standard treatment is glucose lowering d
Sponsors
Abadan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 85 Years
Inclusion criteria
Inclusion criteria: Age 25-25 years Male and female patients Completion of diagnostic criteria for type 2 diabetes mellitus The desire to participate in the study with the ability to understand the relevant information and complete the informed consent form
Exclusion criteria
Exclusion criteria: Use of warfarin and other coumarin substitutes by the patient Use of increasing blood glucose drugs such as antidepressants (triangles), beta-adrenergic blockers, corticosteroids, diazoxide, diuretics, epinephrine, estrogen, glucagon, isoniazid, lithium, phenothiazines, phenytoin, salicylates and triamterene Use of glucose lowering drugs, including acetaminophen, alcohol, anabolysin steroids, gemfibrosil, monoamine oxidase inhibitors, propranolol, tolazamide, and tolbutamide History of uncontrolled hypertension, congestive heart failure and other cardiovascular disease, liver disease, kidney disease, or any metabolic and clinical disorder, except diabetes mellitus Patients with dangerous disease Renal dysfunction (glomerular filtration rate less than 60 ml / min / 1.73 mm3 of surface area) Participants with recent weight loss or weight gain more than 5% of body weight within 3 months People with type 1 diabetes or other chronic diseases such as stroke and cancer that may affect physical activity Pregnant and lactating women People with psychological illnesses Patient with type 2 diabetes under insulin therapy Smoking during the testing period (increasing blood glucose levels) Patients with sickle cell anemia, thalassemia, Chronic renal failure affecting the hemoglobin A1c Any circumstances that, according to the researcher, do not justify the participation of individuals in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Colorimetric method using spectrophotometer.;2 hour post prandial. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Colorimetric method using spectrophotometer.;At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Calorimetry with ELISA reader.;Serum glutathione peroxidase enzyme activity. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Calorimetry with ELISA reader.;Serum catalase enzyme activity. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Calorimetry with ELISA reader.;Serum LDL level. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Colorimetric method using spectrophotometer.;Serum HDL levels. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Colorimetric method using spectrophotometer.;Serum total cholestrol. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin capsule. Method of measurement: Colorimetric method using spectrophotometer.;Serum triglyceride levels. Timepoint: At the beginning of the study (before the start of the study) and 90 days after the start of taking the Asafin c | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahshid Naghashpour
Abadan Faculty of Medical Sciences
Outcome results
None listed